Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Alnylam’s Amvuttra Could Become First-Line Therapy for ATTR-CM, Says Expert
With its recent label expansion in Japan, Alnylam’s RNAi drug Amvuttra (vutrisiran) is seen as a strong contender for first-line therapy in the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), according to a cardiology expert. Hiroaki Kitaoka, professor of geriatric and…
To read the full story
Related Article
- Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
- Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
BUSINESS
- Medipal Names Imagawa as New CEO in 1st Leadership Change in 14 Years
September 9, 2026
- Kyowa Kirin’s nAMD Med Misses Mark in Global PII Study
September 9, 2026
- Belite Bio Files Stargardt Drug Tinlarebant in Japan
September 9, 2026
- AstraZeneca, Kyushu Electric Power Unit Pilot EV Charging Service
September 9, 2026
- Jardiance Takes Top Spot in Four Promotion Channels in July: Intage
September 9, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…